LONDON – AstraZeneca is working with Quintiles to find out if medication reminders help COPD patients adhere to therapy. The two companies have embarked on a clinical study involving 380 people who will use Symbicort inhalers connected to a BreatheMate patient support tool. BreatheMate monitors daily inhaler use and sends the data via Bluetooth to a phone. One group in the study will also receive audio-visual reminders to take their medication, while a second group will not. Leaders of the study report that COPD patients with lower adherence rates tend to have higher overall healthcare costs, and those with higher adherence rates experienced fewer hospitalizations and have lower healthcare costs.
You are here: / / AstraZeneca tracks adherence rates for COPD inhaler